Grifols, S.A. has grown revenue 14% a year over three years and 7.2% a year over five, with earnings per share compounding at −6.3%. Revenue growth, 3-year annual rate: +14% (Drug Manufacturers - General median +6.3%). Revenue growth, 5-year rate: +7.2%, growth has picked up over the last three years. Earnings per share, 3-year rate: −6.3%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 10, FY2015 to FY2024, as filed.

GRFSGrifols, S.A.

Healthcare

$7.45-24% 1Y

$7.45

$7.0052 weeks$10.02

Is it growing?

Mixed

Neither accelerating nor breaking down: earnings up +283% year on year, but operating margin narrowing (−2.1 points).

1 good, 1 to watch, 1 neutral

Revenue trend+9% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +7% a year.

Earnings trend+283% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction−2.1 points operating

Trailing-twelve-month operating margin, 16.5% now against 18.7% a year earlier.

All from SEC EDGAR, as of Dec 31, 2024.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is GRFS growing?

Grifols, S.A. has grown revenue 14% a year over three years and 7.2% a year over five, with earnings per share compounding at −6.3%.

+14%

Revenue growth, 3-year annual rate · Drug Manufacturers - General median +6.3% · steady growth, ahead of inflation · compounded from fiscal years as filed

Revenue growth, 5-year rate: +7.2%
Revenue growth, 5-year rate · +14% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: −6.3%
Earnings per share, 3-year rate · revenue +14% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 10
Years of annual history on file · FY2015 to FY2024, as filed